Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Sarcoma, Ewing 1Pathologic Complete Response 1Osteosarcoma 1Neutropenia 1Neoplasms 1Myelosuppression 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × trilaciclib × Clear all
NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡